Orgenesis ORGS shares are trading higher on Wednesday.
The company announced a cell-based vaccine platform targeting COVID-19 and other existing and emerging viral diseases.
Orgenesis is a biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization.
Orgenesis shares were trading up 14.84% at $6.92 at time of publication on Wednesday. The stock has a 52-week high of $8.20 and a 52-week low of $2.35.
Related Links:
Valeritas Insulin Device For Diabetics Accepted Under Managed Formulary
Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For $950M
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
